Oncology Clinical Trials Market Report 2025

The oncology clinical trials market size has grown strongly in recent years. It will grow from $14.04 billion in 2024 to $14.99 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the rising prevalence of cancer cases, increasing adoption of targeted cancer therapies, growing awareness of early cancer detection and screening, the expanding number of oncology-focused clinical research organizations, and higher patient participation facilitated by advocacy groups.

The oncology clinical trials market size is expected to see strong growth in the next few years. It will grow to $19.22 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to the rising demand for personalized and precision oncology treatments, increased focus on rare and orphan oncology indications, growing adoption of decentralized and virtual oncology trials, and expanding use of genomic sequencing for patient selection. Key trends expected during the forecast period include advancements in biomarker-based trials, the application of advanced data analytics in trial design, innovations in immuno-oncology therapies, integration of artificial intelligence and machine learning, development of patient-centric trial models, and incorporation of real-world data in trial evaluation.

The rising incidence of cancer is expected to drive the growth of the oncology clinical trials market in the coming years. Cancer incidence refers to the number of new cancer cases within a specific population over a defined period. This increase is largely attributed to unhealthy lifestyle habits, including poor diet, lack of physical activity, tobacco use, and excessive alcohol consumption, which elevate the risk of developing various types of cancer. Oncology clinical trials play a critical role in advancing cancer treatment by evaluating new therapies and interventions, improving patient outcomes through evidence-based research. They accelerate medical innovation by assessing the safety and efficacy of treatments, supporting progress in cancer prevention, diagnosis, and care. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that cancer cases diagnosed in Australia reached 160,570 in 2022, up by 3,789 cases from 156,781 in 2021. Consequently, the rising cancer incidence is fueling the growth of the oncology clinical trials market.

Key players in the oncology clinical trials market are focusing on technologically advanced solutions, such as AI-driven bioinformatics platforms, to enhance data analysis, speed patient recruitment, and optimize trial outcomes. Advanced bioinformatics platforms are sophisticated software systems that use computational tools and algorithms to collect, analyze, and interpret complex biological and clinical data for research and healthcare purposes. For instance, in September 2023, Deep 6 AI, a US-based healthcare technology company, launched an AI-powered genomics module designed to accelerate enrollment in precision medicine and oncology clinical trials. This module utilizes artificial intelligence and natural language processing to extract both structured and unstructured genomics data from electronic medical records, enabling real-time patient identification and accurate matching based on specific genetic markers. It allows researchers to search millions of records for over 19,000 genes and 30,000 mutation names, significantly speeding up patient recruitment and improving clinical trial efficiency.

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for \$66.9 million. This acquisition aims to strengthen Coherus’s immuno-oncology pipeline, expand therapies targeting the tumor microenvironment, and enhance the clinical potential of its PD-1 inhibitor, toripalimab. Surface Oncology Inc. is a US-based clinical-stage immuno-oncology company conducting trials for novel cancer therapies.

Major players in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.

North America was the largest region in the oncology clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncology clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oncology clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Oncology clinical trials are research studies that assess new treatments, drugs, or approaches for preventing, detecting, or managing cancer in humans. These trials are designed to evaluate the safety, efficacy, and potential side effects of interventions before they become widely available. Oncology clinical trials play a crucial role in improving clinical outcomes and advancing cancer care.

The primary phases of oncology clinical trials include phase I, phase II, phase III, and phase IV. Phase I trials are early-stage studies focused on evaluating the safety, tolerability, and optimal dosage of a new cancer treatment, while also examining how the drug is absorbed, distributed, metabolized, and excreted in the body. Their study designs include interventional, observational, and expanded access trials, and therapeutic modalities encompass immunotherapy, targeted therapy, chemotherapy, cell and gene therapy, and others. These trials address indications such as lung cancer, breast cancer, colorectal cancer, prostate cancer, blood cancers, and more, with sponsors including pharmaceutical and biotech companies, academic and research institutions, government organizations, and others.

The oncology clinical trials market research report is one of a series of new reports that provides oncology clinical trials market statistics, including oncology clinical trials industry global market size, regional shares, competitors with an oncology clinical trials market share, detailed oncology clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the oncology clinical trials industry. This oncology clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology clinical trials market includes revenues earned by entities through designing and conducting cancer-related clinical research studies, providing patient recruitment and enrollment services, supplying oncology-specific laboratory testing and diagnostics, and managing data collection, monitoring, and regulatory compliance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.